VB
Viva Biotech Holdings
VBIZF · OTC
$0.19 +0.00% (+$0.00)
Market Cap ¥2.66B
P/E Ratio 12.44x
Div. Yield -
ROE 5.47%
Bulios Fair Price
$0.15
21.8% downside
Current Price
$0.19
Undervalued Fair Value Overvalued
According to Bulios Fair Price, VBIZF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
83 /100
Cheap EV/EBITDA 7.32x
P/S 1.58x
P/B 0.67x
Growth
6 /100
Declining FCF growth 13.65%
Book val. growth 3.52%
Rev. growth 10.87%
Profitability
56 /100
Moderate Net margin 12.71%
Op. margin 11.17%
FCF margin 5.22%
Quality
18 /100
Poor ROE 5.47%
ROA 2.97%
Asset turnover 0.23x
Debt
86 /100
Low Current ratio 1.50x
Int. coverage 5.15x
Net debt/EBITDA 0.56x
Stability
46 /100
Moderate Rev. volatility 3.87%
EPS volatility 81.24%
Profitable years 2
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about VBIZF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Chen Cheney Mao
Employees
2,169
Headquarters
Shanghai
Upcoming events
01 APR
Earnings
Upcoming earnings report